Objective: To formulate and characterize. Phenobarbital sodium loaded sublingual patch using biodegradable, mucoadhesive, fast-dissolving natural polymer pullulan for immediate management of epileptic seizures. Methods: Phenobarbital sodium loaded sublingual patches were prepared by the solvent casting method and were subjected to various physicochemical evaluation parameters to find the optimized sublingual patch. The in vitro drug release study and kinetic model of the optimized formulation was also carried out. The stability study of the optimized Phenobarbital sodium loaded sublingual patch was also done. Results: From in vitro drug release study, it was found that Phenobarbital sodium loaded sublingual patch (S4) exhibited a maximum drug release of 96.24±1.27% at the end of 60 min compared to other formulations indicating a faster drug release from the formulation with release kinetics as Higuchi diffusion model. In fact, a notable release data was obtained between 0.5 to 8 min by all formulations, specifically S4 formulation (20.84±1.97% and 77.22±2.41% drug release at the end of 0.5 min and 8 min respectively) showed a better percentage release profile in comparison with other formulations. Such a trend is vital to deliver the drug at a faster rate to promote immediate effect for managing the fatal and complicated seizure. Considering the physicochemical property and in vitro drug release data, S4 formulation was regarded as an optimized one. The stability study also confirmed that S4 formulation is stable at refrigeration conditions. Conclusion: The formulated Phenobarbital sodium loaded sublingual patch is an effective drug delivery carrier which enables faster drug release to manage epileptic seizure.
Parkinson's disease (PD) is a neurodegenerative disorder that primarily impinges the dopaminergic neurons in a particular region of Brain termed as Substantia Nigra. The disease affects more than 1900 people per 100,000 aged 80 years and above. Furthermore, men are 1.5 times more prone than their counterpart. Potential biomarkers escalated the precise diagnosis and helped to initiate treatment to limit its adversity. The current therapeutic schemes are focused on administration of Dopamine precursor, Dopamine agonist, Monoamine oxidase (MAO) inhibitor, Catechol-o-methyl transferase (COMT) inhibitors and deep brain stimulation. The CNS delivery focuses mainly on increasing the dopamine level in the brain. CNS drug delivery faces a crucial challenge of crossing Blood Brain Barrier. Blood-Brain Barrier Penetration can be attained by several techniques. Conventional drug therapy yields harmful affects to the patients without much therapeutics. It is visible that crossing BBB is quite strenuous process. It is mandatory for developing a novel approach untangling these situations. Nanotechnology-based formulations like nanosuspensions, nanotubes etc. promotes the penetration of drug across the sophisticated barrier without creating any deterioration to cells or organs. Several novel routes for drug administration reduce dose intake with increased and precise pharmacological action. Nanoformulations and Novel routes of drug administration are a promising tool to enhance the action of drug which helps to abate the symptoms of the Disease and assist in the betterment in treatment.
Objective: To formulate and evaluate propranolol hydrochloride topical gel for overcoming the limitations and low oral bioavailability associated with conventional therapy. Methods: The propranolol hydrochloride topical gels were prepared by the cold mechanical method. The preliminary evaluation and further characterisation studies was conducted to find the optimised formulation. The in vitro release and ex vivo permeation studies were investigated. The histopathological studies and stability studies was also assessed. Results: The propranolol hydrochloride topical gel was successfully prepared. The in vitro release of optimized topical propranolol hydrochloride gel formulation (G2) showed the highest cumulative percentage drug release that is, 95.55%±0.15 after 7.5 h. (G2) the formulation showed a higher flux value of 4.61μg/cm2/h. The histopathological study using pig skin revealed that the optimized formulation was found to be safe for topical application. Conclusion: The formulated topical gel containing propranolol Hydrochloride seems to be a promising dosage form for enhanced skin delivery of propranolol hydrochloride in treating Infantile Hemangioma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.